Latest Biotechnology News

Page 8 of 101
Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.
Ada Torres
Ada Torres
30 Sept 2026
Ocean Sciences delivered a sharp increase in seaweed revenue during FY2026, but the audited report also records a A$1.612 million continuing-operations loss, A$2.319 million operating cash outflow and material uncertainty over its ability to continue as a going concern. The renamed ASX-listed group is now seeking up to A$3 million while building out its Indonesian platform.
Ada Torres
Ada Torres
29 Sept 2026
Neuren says its partner Acadia has received a US Notice of Allowance for a trofinetide patent that could protect weight-banded dosing through 28 March 2041. The patent has not yet formally issued, but the allowance could extend US protection by almost five years beyond the existing method-of-use patent.
Ada Torres
Ada Torres
29 Sept 2026
Memphasys will receive an A$3.5 million advance from major shareholder Peters Investments to expand Felix production, inventory and sales capacity as repeat orders emerge across international markets. The funding carries a 12.5% interest rate, potential equity dilution and requires shareholder and ASX approvals before the convertible notes can be issued.
Ada Torres
Ada Torres
29 Sept 2026
Cynata Therapeutics (ASX:CYP) has reported a $9.25 million loss, negative net assets and a material uncertainty over going concern after its two major clinical trials failed to demonstrate efficacy. The company has since cut its workforce to zero, shifted management to the board and secured a $600,000 R&D tax incentive loan while it considers the future of its Cymerus platform.
Ada Torres
Ada Torres
28 Sept 2026
Paradigm Biopharmaceuticals will keep its ASX securities suspended until at least 30 September while it reviews interim Phase 3 data and assesses the operational and financial consequences. The company also remains in discussions with Obsidian Global GP, LLC, but has not disclosed the trial results or their direction.
Ada Torres
Ada Torres
28 Sept 2026
Mesoblast has secured FDA approval to add a new potency assay to commercial release and stability testing for Ryoncil, its approved cell therapy for paediatric graft-versus-host disease. The regulatory decision supports tighter monitoring as manufacturing processes evolve, but the company disclosed no direct financial impact or clinical outcome data.
Ada Torres
Ada Torres
24 Sept 2026
Prescient Therapeutics has raised approximately $6 million through its Share Purchase Plan and a shortfall placement, giving PTX-100 additional funding beyond a key clinical review in December. The next test is whether early results support a move into Phase 2b development.
Ada Torres
Ada Torres
23 Sept 2026
Actinogen Medical has completed the final patient visit in its 247-participant XanaMIA Alzheimer’s disease trial, keeping topline results on track for November 2026. The milestone closes patient participation in the pivotal study, but provides no indication yet of whether Xanamem improved outcomes.
Ada Torres
Ada Torres
23 Sept 2026
Dimerix has drawn A$17 million from a non-dilutive facility, giving the biotech funding it says is sufficient to complete the ACTION3 Phase 3 trial of DMX-200 and continue developing DMX-652. A further A$17 million remains available, although repayment depends partly on future licensing income, milestones or capital-market access.
Ada Torres
Ada Torres
23 Sept 2026
AdAlta has secured a formal US FDA pre-IND meeting for EW-001, moving its mesothelioma CAR-T therapy into a critical regulatory review. The November meeting will test the company’s Australian manufacturing, remaining studies and proposed Phase 1 trial before the more expensive stages of development begin.
Ada Torres
Ada Torres
23 Sept 2026
Nyrada has secured AU$12.0 million from institutional and sophisticated investors, with a further AU$2.0 million shareholder purchase plan planned, giving the biotech funding to advance its Xolatryp clinical programs. The raise also carries substantial dilution and an unusually large proposed director subscription worth AU$5.125 million, subject to shareholder approval.
Ada Torres
Ada Torres
21 Sept 2026

Browse the archive

Full archive